Cargando…
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
SLFN11 is a recently discovered protein with a putative DNA/RNA helicase function. First identified in association with the maturation of thymocytes, SLFN11 was later causally associated, by two independent groups, with the resistance to DNA damaging agents such as topoisomerase I and II inhibitors,...
Autores principales: | Ballestrero, Alberto, Bedognetti, Davide, Ferraioli, Domenico, Franceschelli, Paola, Labidi-Galy, Sana Intidhar, Leo, Elisabetta, Murai, Junko, Pommier, Yves, Tsantoulis, Petros, Vellone, Valerio Gaetano, Zoppoli, Gabriele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625715/ https://www.ncbi.nlm.nih.gov/pubmed/28969705 http://dx.doi.org/10.1186/s12967-017-1296-3 |
Ejemplares similares
-
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021) -
SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022) -
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
por: Terzic, Julie, et al.
Publicado: (2020) -
Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015) -
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)